Stockscreener 앱 받기
1.38
4.17%
-0.06
시간 외 거래:
1.41
0.03
+2.17%
Bone Biologics Corp 주식(BBLG)의 최신 뉴스
BBLG | Bone Biologics Corp Common Insider Trading - Quiver Quantitative
BBLG Q1 2026 Earnings: EPS Beat on Narrower Loss, Stock Dips SlightlyDiluted EPS Report - newsline.com
Bone Biologics Corp (BBLG) Edges Lower Amid Light Trading – Key Support Level in FocusBreadth Thrust - newsline.com
Bone Biologics Corp Warrants (BBLGW) Remains Steady at $14.0, Navigating Key Support and Resistance LevelsEnding Diagonal - newsline.com
Bone Biologics Corp Warrants (BBLGW) Surge Over 9%: Key Levels and OutlookOBV Trend Line - newsline.com
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Asia Demineralized Bone Matrix Allograft MaterialsMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
NUWE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
World Demineralized bone matrix allograft materialsMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
BBLG Q1 2026 Earnings: Smaller-than-Expected Loss on No Revenue as Bone Graft Developer Continues R&D ProgressGAAP Earnings Report - The Legal Advocate
Bone Biologics Corp (BBLG) Surges 5.24% — Can It Hold Above Key Resistance?Factor Rotation - The Legal Advocate
Bone Biologics Corp (BBLG) Tests Support After Marginal DeclinePCR Mean Reversion - newsline.com
Bone Biologics Corp (BBLG) Rises 3.28% as Stock Approaches Resistance LevelFundamental Weighted - The Legal Advocate
Bone Biologics Corp Warrants (BBLGW) Holding Steady at $14.15 After a Flat SessionBullish Pattern Stocks - The Legal Advocate
World Bone Graft SubstitutesMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
BBLG Q1 2026 Earnings: Narrower-than-Expected Loss as Company Advances Bone Graft PlatformROIC Trend Report - Newser
BBLG Q1 2026 Earnings: Narrowed Loss Beats Estimates as Bone Biologics Advances PipelineBook Value Growth - The Legal Advocate
BBLG Q1 2026 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock DeclinesAI Trading Community - Newser
Bone Biologics Corp (BBLG) Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares DipSocial Signal Watchlist - Newser
BBLG Q1 2026 Earnings: Narrower-than-Expected Loss as Bone Biologics Advances DevelopmentFree Stock Community - Newser
Bone Biologics extends rhNELL-1 protein shelf life to 29 months - Investing.com
Spine fusion protein from Bone Biologics now lasts 29 months - Stock Titan
VBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VBIO PE Ratio & Valuation, Is VBIO Overvalued - Intellectia AI
Bone Biologics (BBLG) flags going concern, cash runway into Q4 2026 - Stock Titan
TradingKey - TradingKey
Bone Biologics Corp expected to post a loss of 54 cents a shareEarnings Preview - TradingView
How Bone Bio (BBLG) translates market opportunities into growth (-3.01%) 2026-05-08Corrective Wave - newsline.com
What Bone Bio (BBLG) is doing that smarter investors notice (Smart Money Exits) 2026-05-07Stock Community Signals - Newser
What Bone Bio BBLG is doing that smarter investors notice Smart Money Exits 20260507Profit Announcement - Newser
Why Bone Bio (BBLGW) is trading below its true worth (Investor Concern) 2026-05-06Stock News - newser.com
Leading Companies Fueling Growth and Innovation in the Spine Biologics Market - openPR.com
BBLGW (Bone Bio) quarterly earnings release excludes core financial metrics, investors seek additional operational disclosures.Revenue Guidance Range - newsline.com
Bone Bio (BBLG) Stock: Volatility Overview (-1.78%) 2026-04-23Crowd Sentiment Stocks - Newser
BBLGW (Bone Bio) quarterly earnings carry no finalized public metrics as the firm wraps up internal financial reviews.Community Sell Signals - Newser
BBLGW (Bone Bio) quarterly earnings data unavailable, stakeholders await updates on core orthobiologics growth plans.Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La
Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Orthobiologics Market - openPR.com
Is First Mid (FMBH) stock still a good play today (Flirts with Breakout) 2026-04-20Social Investment Platform - Cổng thông tin điện tử tỉnh Lào Cai
Aug Weekly: What is Bone Biologics Corporation Equity Warrants revenue forecastExit Point & Fast Moving Market Watchlists - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
Entry Recap: What is the Moat Score of Bone Biologics CorporationQuarterly Performance Summary & Consistent Return Strategy Ideas - baoquankhu1.vn
Biocon Announces U.S. Commercial Launch of Bosaya™ and Aukelso™, Denosumab Biosimilars - PharmiWeb.com
Is Bel Fuse (BELFB) Stock at a Peak | Price at $204.62, Down 0.01%Community Driven Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
BBLGW Stock Analysis: Bone Biologics Corp Warrants Flat at 21 Amid Calm Biotech Trading - The Legal Advocate
Market Structure, Emerging Trends, and Key Player Analysis in the Orthobiologics Devices and Equipment Sector - openPR.com
Earnings Update: Whats the profit margin of Aptiv PLC2026 Rallies & Capital Protection Trading Alerts - baoquankhu1.vn
TPB Stock Analysis: Turning Point Brands Inc drops 14.45% to 74.25 in selloff - Cổng thông tin điện tử tỉnh Lào Cai
1.27%
1.43%
자본화:
|
볼륨(24시간):